A detailed history of Kbc Group Nv transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Kbc Group Nv holds 1,356 shares of PTGX stock, worth $62,999. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,356
Previous 1,356 -0.0%
Holding current value
$62,999
Previous $47,000 29.79%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 17, 2024

BUY
$24.66 - $34.8 $3,797 - $5,359
154 Added 12.81%
1,356 $47,000
Q1 2024

May 08, 2024

BUY
$21.79 - $32.15 $26,191 - $38,644
1,202 New
1,202 $35,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.28B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.